drugset / Trial / NCT06134271
Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This multicenter, prospective, cohort study enrolled patients with metastatic hormone-sensitive prostate cancer who had been treated with other novel endocrine or systemic regimens (excluding patients treated with pre-order chemotherapy alone or bicalutamide); To observe the efficacy and safety of rezvilutamide alone or in combination with abiraterone in hormone-sensitive prostate cancer patients with PSA progression following prior sequence therapy.
Timeline
- Start
- 2023-11-15
- Primary completion
- 2025-04-30
- Completion
- 2026-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Subject | Rezvilutamide | Small molecule | 240 mg | Oral |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |